Haemophilus b conjugate vaccine (tetanus toxoid conjugate, Sanofi)

b型流感嗜血杆菌结合疫苗（赛诺菲）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameHaemophilus b conjugate vaccine (tetanus toxoid conjugate, Sanofi)
Drug Alias NameHaemophilus Type b Conjugate Vaccine ( Sanofi)B型嗜血杆菌结合疫苗（破伤风类毒素结合物，赛诺菲）ActHIB安尔宝DF-098
ClassificationVaccines > National Immunization Program > Non-immunization program vaccine(Class II)Vaccines > Biological material > Toxoid vaccineVaccines > Biological material > Bacterial vaccine +[5] 
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsHaemophilus Infections
Global Approved IndicationsHaemophilus Infections
Approved Indications in ChinaHaemophilus Infections
Original Approved Country/TerritoryUnited States
Original Approved Date1993/03/30
Country/TerritoryUnited StatesSwedenMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSanofi
China Registration ClassN/A

Develop Information

Active CompaniesSanofi Pasteur
Inactive CompaniesViscogel Ab
Active IndicationsHaemophilus Infections
Inactive IndicationsN/A

Other Information

ATC CodeJ07AG01
Related LinksN/A